Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.77)
# 3,959
Out of 5,072 analysts
58
Total ratings
34%
Success rate
-23.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.93 | +85.50% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $29.42 | +5.37% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.22 | +1,457.38% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $9.07 | +131.53% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.39 | -7.24% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.36 | +577.97% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.48 | +8,008.11% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $5.19 | +381.70% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $110.00 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $4.35 | +45,877.01% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.34 | +422.39% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.80 | +163.16% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $18.80 | +219.15% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.65 | +263.64% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.78 | +164.55% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $2.23 | +10,662.33% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $3.21 | +5,569.78% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.25 | +31,721.80% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.16 | +380.77% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.63 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.25 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.34 | +156.41% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.06 | +246.53% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $20.72 | +50,575.68% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $4.92 | +652.03% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $65.69 | +356.69% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $784.61 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $105.65 | -15.76% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $151.58 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $0.93 | +1,621,521.62% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.96 | +17,042.86% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.03 | +346.65% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.93
Upside: +85.50%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $29.42
Upside: +5.37%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.22
Upside: +1,457.38%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $9.07
Upside: +131.53%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.39
Upside: -7.24%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.36
Upside: +577.97%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.48
Upside: +8,008.11%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $5.19
Upside: +381.70%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $110.00
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $4.35
Upside: +45,877.01%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.34
Upside: +422.39%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $3.80
Upside: +163.16%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $18.80
Upside: +219.15%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.65
Upside: +263.64%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.78
Upside: +164.55%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $2.23
Upside: +10,662.33%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $3.21
Upside: +5,569.78%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.25
Upside: +31,721.80%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.16
Upside: +380.77%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $13.63
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.34
Upside: +156.41%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.06
Upside: +246.53%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $20.72
Upside: +50,575.68%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $4.92
Upside: +652.03%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $65.69
Upside: +356.69%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $784.61
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $105.65
Upside: -15.76%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $151.58
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $0.93
Upside: +1,621,521.62%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.96
Upside: +17,042.86%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.03
Upside: +346.65%